# What has research learned about joint shots?

*What Research Says About Joint Injections Gilbert*

> Research on joint injections Gilbert patients may consider shows how steroid, gel, and PRP shots differ and where results remain uncertain.

## Which finding helps you most?

Steroid shots tend to help sooner than they help for long. Group research can guide your choice, but it can't promise relief for your joint.

## How long might each kind help?

Steroid shots show clearer relief early than they do months later. Their effect often becomes smaller as the weeks pass.

Gel shots show only small average changes when experts combine several medical studies. Some people feel help, but many may notice little difference.

Doctors use PRP as a short name for platelet-rich plasma. They make it by spinning blood and gathering its liquid plasma portion.

That portion holds extra platelets, tiny blood parts carrying healing signals. Some studies favor PRP later, while a large trial found no more relief than salt water.

## What are the limits of each choice?

Steroid relief may fade, and repeated use needs a doctor's review. Gel brings only a small average change, and coverage varies.

PRP studies don't agree, partly because clinics prepare it in different ways. Health plans often leave its cost to you.

People also hurt for different reasons. Swelling, severe wear, and a sore tendon won't always respond alike.

An exam can show which research best fits your cause. Even then, no kind of shot promises relief.

## What if the soreness still limits you?

The natural pain treatments at QC Kinetix include both forms of PRP. A doctor makes each form with a small amount of your blood.

In concentrated PRP, platelets make up more of the prepared liquid. Those tiny blood parts carry signals the body uses while healing.

First, the doctor finds the likely cause of your soreness during daily activity. Have the doctor explain when any benefit could begin and when it might fade.

Also ask about cost, greater soreness afterward, and care if it fails. Consider each of those limits before making your decision.

## Sources

1. A 2022 BMJ systematic review and meta-analysis of 169 trials (21,163 participants) found viscosupplementation produced only a small pain reduction versus placebo (SMD -0.08, 95% CI -0.15 to -0.02; about -2.0 mm on a 100 mm VAS), below the minimal clinically important difference, and trial sequential analysis indicated conclusive evidence of clinical equivalence with placebo since 2009.
   Pereira TV, et al. — [Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/36333100/). *BMJ*, 2022. DOI: 10.1136/bmj-2022-069722.
2. The 2015 Cochrane review of 27 trials (1,767 participants) found intra-articular corticosteroid better than sham for knee OA pain (SMD -0.40, 95% CI -0.58 to -0.22; NNTB 8), but the benefit decayed with time: moderate at 1-2 weeks, small at 13 weeks, and no evidence of any effect at 26 weeks. All outcomes were graded LOW quality.
   Jüni P, et al. — [Intra-articular corticosteroid for knee osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/26490760/). *Cochrane Database Syst Rev*, 2015. DOI: 10.1002/14651858.CD005328.pub3.
3. A 2025 network meta-analysis restricted to LARGE randomized trials (57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials; excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6, while hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11) and higher odds of dropouts due to adverse events (OR 2.01) and serious adverse events (OR 1.86) than placebo.
   Pereira TV, et al. — [Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/39265924/). *Osteoarthritis Cartilage*, 2025. DOI: 10.1016/j.joca.2024.08.014.
4. In a 2-year double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, 40 mg intra-articular triamcinolone every 12 weeks produced significantly greater cartilage volume loss than saline (index compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with no significant difference in knee pain.
   McAlindon TE, et al. — [Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/28510679/). *JAMA*, 2017. DOI: 10.1001/jama.2017.5283.
5. A 2-year double-blind RCT of triamcinolone every 3 months versus saline found NO difference in joint space loss between groups and significantly improved pain and stiffness with repeated steroid injections, and the authors concluded that long-term intra-articular steroid injection is safe for the anatomical structure of the knee.
   Raynauld JP, et al. — [Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial.](https://pubmed.ncbi.nlm.nih.gov/12571845/). *Arthritis Rheum*, 2003. DOI: 10.1002/art.10777.
6. The RUbICOn mixed-methods HTA study, commissioned specifically to address uncertainty about recurrent injections, combined a UK primary-care cohort (2005-2020) linked to hospital data with a safety analysis, patient and clinician interviews, and a three-round Delphi to set research priorities - the current formal acknowledgement that the long-term risks and benefits of repeat injections remain unresolved.
   Whitehouse MR, et al. — [RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study.](https://pubmed.ncbi.nlm.nih.gov/41217479/). *Health Technol Assess*, 2025. DOI: 10.3310/LFAJ9337.
7. A 2024 network meta-analysis of 48 studies (9,338 knees) at minimum 6-month follow-up ranked PRP first for pain and function (SUCRA 91.5), then BMAC (76.5) and hyaluronic acid (53.1), with corticosteroid (15.2) barely above placebo (13.7) at that time point.
   Jawanda H, et al. — [Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/38331363/). *Arthroscopy*, 2024. DOI: 10.1016/j.arthro.2024.01.037.
8. A meta-analysis of 14 placebo cohorts (1,076 patients) found intra-articular NORMAL SALINE alone produced statistically and clinically meaningful improvement in VAS pain and WOMAC scores lasting up to 6 months - meaning a large share of the improvement people attribute to an injection is not attributable to the drug in the syringe.
   Saltzman BM, et al. — [The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies.](https://pubmed.ncbi.nlm.nih.gov/28027657/). *Am J Sports Med*, 2017. DOI: 10.1177/0363546516680607.
9. The FTC's Health Products Compliance Guidance requires that health-benefit claims be supported by competent and reliable scientific evidence - generally randomized, controlled human clinical testing - and holds advertisers responsible for both express and implied claims, including implied claims of efficacy carried by testimonials.
   U.S. Federal Trade Commission — [Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance). *U.S. Federal Trade Commission*, 2022.
10. The RESTORE randomized trial (288 participants, leukocyte-poor PRP, 3 weekly injections) found no significant difference from saline placebo at 12 months in knee pain (-2.1 vs -1.8 points; difference -0.4, 95% CI -0.9 to 0.2) or in medial tibial cartilage volume (-1.4% vs -1.2%), with 29 of 31 secondary outcomes also showing no between-group difference.
   Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415.
11. The 2025 Cochrane living review of stem cell injections for knee OA (25 trials, 1,341 participants) found stem cell injection MAY slightly improve pain and function up to six months versus placebo (pain 1.2 points better on a 0-10 scale; function 14.2 points better on 0-100), but rated the evidence LOW certainty for both, downgraded for indirectness and suspected publication bias, with up to three larger RCTs withdrawn before reporting results.
   Whittle SL, et al. — [Stem cell injections for osteoarthritis of the knee.](https://pubmed.ncbi.nlm.nih.gov/40169165/). *Cochrane Database Syst Rev*, 2025. DOI: 10.1002/14651858.CD013342.pub2.
12. FDA's HCT/P guidance sets out the minimal-manipulation and homologous-use criteria that decide whether a human cell or tissue product is regulated solely under 21 CFR Part 1271 (section 361) or requires a biologics licence; cell-based orthopaedic injections that fall outside those criteria are unapproved drugs and biological products, and no cell-based product is FDA-approved to treat osteoarthritis.
   U.S. Food and Drug Administration — [Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and FDA Staff](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal). *U.S. Food and Drug Administration*, 2020.
13. An analysis of 37 randomized PRP trials found no significant difference in qualitative conclusions or outcome scores between industry-affiliated and non-industry-affiliated studies; overall, 19 of 37 (51.4%) reported PRP as favourable and 18 (48.6%) found no difference from comparators.
   Ta CN, et al. — [The Influence of Industry Affiliation on Randomized Controlled Trials of Platelet-Rich Plasma for Knee Osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/36594496/). *Am J Sports Med*, 2023. DOI: 10.1177/03635465221140917.

## What if the soreness keeps returning?

A medical provider examines the joint and asks when the soreness began. Bring earlier X-rays, your medicine list, and notes about painful tasks.

The provider explains which non-surgical choices may fit your cause. Ask about the full price, recovery, and warning signs before deciding.

Book a free consultation: <https://joint-pain.qckaz.com/?src=jointinjectionsgilbert.com>

---

Ease the soreness safely and know when to get it checked.

Learn what may ease joint soreness at home, when an exam matters, what common shots contain, and where to find nearby care.

Gilbert guidance on joint soreness, including likely causes, home care, costs, warning signs, and nearby care.

This site is operated by the owners of the QC Kinetix clinics serving the Phoenix area, including the Chandler location nearest Gilbert, so read it as first-party writing from a business that benefits when you book — which is exactly why every number on it carries a source you can open.

© 2026 The Gilbert Joint Ledger. General education about procedures and prices, not medical advice about your joint; talk to a clinician about your own case.